title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Project information and funding | This trial was executed under the model project of Social Impact Bond—one of the styles of Pay for Success policy constructed by the City of Yokohama—with a business contract between the City of Yokohama, Kids Public, Inc., the University of Tokyo, and other stakeholders. Kids Public, Inc. collected personal informatio... | PMC10294407 | ||
Discussion | depression, depressive symptoms | Compared to the participants assigned to the usual care group, those assigned to the mHealth group—where they could use mHealth consultation services according to their needs free of charge—had a lower risk of elevated postpartum depressive symptoms three months after delivery. Women assigned to the mHealth group tende... | PMC10294407 | |
Conclusions | This was the first randomized controlled trial to investigate the effectiveness of mHealth consultation services in preventing PPD during the COVID-19 pandemic. Our study showed the considerable potential of mHealth interventions and possible mechanisms to prevent PPD and ensure equity in services in real-world setting... | PMC10294407 | ||
Acknowledgements | Hashimoto | HASHIMOTO, RECRUITMENT | Mitsuru Nakao, Co-Governance and Creation Division, Policy Bureau, the City of Yokohama; Naoya Hashimoto, Kids Public, Inc.; and Daisuke Shigemi, Kids Public, Inc., discussed how to implement this study in a real-world setting with our study team. Yuji Watanabe, the City of Yokohama; Kenta Tamura, the City of Yokohama;... | PMC10294407 |
Authors’ contributions | YA and NK had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. | PMC10294407 | ||
Funding | This trial was funded by the City of Yokohama. The service provider, Kids Public, Inc. offered the mobile health consultation service funded by the City of Yokohama. This work was supported by the Japan Society for the Promotion of Science (No. 26670306, 18H04071). Before the study was constructed, the University of To... | PMC10294407 | ||
Availability of data and materials | The data are available from the corresponding author on reasonable request. | PMC10294407 | ||
Declarations | PMC10294407 | |||
Ethics approval and consent to participate | The study was conducted in accordance with the principles of the Declaration of Helsinki and relevant local/international guidelines. The study protocol was approved by the ethical review board of the University of Tokyo (no. 2019347NI). All participants provided informed consent to participate in this study by submitt... | PMC10294407 | ||
Consent for publication | Not applicable. | PMC10294407 | ||
Competing interests | DN2 reports personal fees from Startia, Inc.; en-power, Inc.; MD.net; and AIG General Insurance Company, Ltd. outside the submitted work. | PMC10294407 | ||
References | PMC10294407 | |||
Methods | anemia, birth anomalies | ADVERSE EVENTS, PRETERM LABOR, PRETERM RUPTURE OF MEMBRANES, ANEMIA | A pilot open-label randomized clinical trial. Participants with confirmed diagnosis of anemia in three tertiary hospitals in Nigeria were studied. Eligible participants were randomized 1:1 to either Mojeaga syrups 50 mls (200mg/50mls) administered three times daily in conjunction with conventional iron therapy (Mojeaga... | PMC10166496 |
Results | deaths, congenital anomalies | ADVERSE EVENTS | Ninety five participants were enrolled and randomly assigned to the Mojeaga group (n = 48) or standard-of-care group (n = 47). The baseline socio-demographic and clinical characteristics of the study participants were similar. At two weeks follow-up the median rise in hematocrit values from baseline (10.00±7.00% vs 6.0... | PMC10166496 |
Conclusion | congenital anomalies, anemia | ANEMIA DURING PREGNANCY, ANEMIA | Mojeaga represents a new adjuvants for standard-of-care option for patients with anemia. Mojeaga remedy is safe for treating anemia during pregnancy and puerperium without increasing the incidence of congenital anomalies, or adverse neonatal outcomes. | PMC10166496 |
Data Availability | All relevant data are within the paper and its | PMC10166496 | ||
Introduction | anemia, constipation, Anemia, IDA, nausea, vomiting | IRON DEFICIENCY ANEMIA, ANEMIA, IRON DEFICIENCY, ANEMIA | Anemia in women is a major public health burden worldwide, particularly in low- and middle-income countries [Iron deficiency anemia (IDA) is often treated with oral iron supplements even in pregnancy. However, due to gastrointestinal side effects such as nausea, vomiting, and constipation, compliance is often poor and ... | PMC10166496 |
Methods | PMC10166496 | |||
Study setting | The study was carried out at the antenatal (obstetrics) clinics of Nnamdi Azikiwe University Teaching Hospital (NAUTH), Nnewi, Enugu State University of Science and Technology Teaching hospital, Parklane, Enugu and Chukwuemeka Odumegwu Ojukwu University Teaching Hospital, Awka, all are tertiary hospitals in South-east ... | PMC10166496 | ||
Study design | This was an open-label randomized clinical trial. | PMC10166496 | ||
Study population | anemia | RECRUITMENT, ANEMIA | The participants comprised obstetrics participants with clinical and laboratory diagnosis of anemia and gave written informed consent before recruitment. The participants were recruited at the antenatal clinics or referred for treatment of their anemia from other hospitals. Participants were recruited before to commenc... | PMC10166496 |
Inclusion criteria | Anemia, anemia | ANEMIA, ANEMIA IN PREGNANCY, ANEMIA | Inclusion criteria included obstetrics adult participants with confirmed clinical and laboratory diagnosis of anemia (hematocrit of <31.5%) and with normal liver and renal function markers or profiles. Anemia was confirmed by prospective expert hematology review. In this study, significant anemia in pregnancy is define... | PMC10166496 |
Exclusion criteria | nausea and vomiting, anemia, cancers, chronic medical disorders | CANCERS, ANEMIA | Pregnant women in the first trimester of pregnancy (because of nausea and vomiting during this period), chronic medical disorders including HIV/AIDS, cancers, etc. and women on chronic medications that cause anemia were excluded. | PMC10166496 |
Randomization and allocation sequence | Following consent, patients at the selected hospitals were screened for eligibility. The participants, eligible for the study, were randomized into two groups (blocks of 4, 1:1 ratio) using block randomization using a randomization table created by a computer software program by a person not involved in the study and a... | PMC10166496 | ||
Blinding of participants, personnel and outcome assessors | Only the outcome assessors were blinded. The study was open-label, with both participants and investigators aware of treatment assignment. | PMC10166496 | ||
Study procedure/Drug administration | anemia | ANEMIA | Participants with a clinical and laboratory diagnosis of anemia presenting in Outpatient Clinic or antenatal clinic of the study hospitals for symptoms or signs of anemia were screened consecutively. All participants underwent routine medical examination that included pulse rate, body weight, blood pressure determinati... | PMC10166496 |
Intervention therapy | Standard doses of 50 mls (200mg/50mls) of Mojeaga were administered three times daily in conjunction with conventional iron therapy (standard-of-care) two times a day (breakfast and dinner) for 2 weeks. | PMC10166496 | ||
Control therapy | Standard/conventional doses of iron therapy (standard-of-care) were administered two times a day (breakfast and dinner) for 2 weeks. The standard-of-care consist of standard doses of one capsule of Astyfer (a supplement with Ferrous fumarate 150mg, Glycine 10mg, L-Histidine hydrochloride H | PMC10166496 | ||
Follow-up | anemia, nausea, vomiting, bowel disturbances | SIDE EFFECT, ADVERSE EVENTS, ANEMIA, ADVERSE EFFECTS, EVENTS, COMPLICATIONS | All participants were followed up in outpatient settings. During each follow-up weekly visit, participants were contacted on phone on weekly basis to assess the level of compliance with the trial drugs. Participants were informed about the usual side effect of hematinic preparations and were told to report nausea, vomi... | PMC10166496 |
Outcome measures | PMC10166496 | |||
Primary | The primary endpoint included changes in the hematocrit level and mean or median hematocrit level at two weeks after initial therapy. | PMC10166496 | ||
Secondary | diarrhea, birth anomaly, pain, dizziness, nausea,, colitis | ADVERSE EVENTS, PRETERM PREMATURE RUPTURE OF MEMBRANES, ADVERSE EFFECTS, SECONDARY, PRETERM LABOR, COLITIS | The secondary endpoints included the proportion of patients with persisting anemic symptoms (epigastric pain, weakness, dizziness) at two weeks after initial therapy, incidence of any maternal adverse events (such as diarrhea, nausea, vomiting, colitis and drop-out from adverse effects) following commencement of therap... | PMC10166496 |
Sample size determination | Since this is a pilot study, we assumed a mean hematocrit level of 29.1% in the control group, mean hematocrit level of 31.5% in the intervention group after the intervention [ | PMC10166496 | ||
Sampling approach | All individuals during the period from February 27, 2020 to February 20, 2022, after satisfying the inclusion and the exclusion criteria were randomly allocated. | PMC10166496 | ||
Drug active dose validation/standardization | The cover of the Mojeaga remedy bottle has a measuring cap which is of 25 mls capacity for uniform administration and validation. Each 500mls of Mojeaga remedy contains 2069.57 mg of active Mojeaga remedy [ | PMC10166496 | ||
Statistical analysis | Data was analyzed using SPSS version 23, IBM Company, USA. The data were expressed as the number (percentage), mean (standard deviation [SD]) or median (±interquartile range), and 95% confidence interval [95% CI] as appropriate. Categorical variables were compared using the Chi-squared test and Fisher’s exact test, as ... | PMC10166496 | ||
Ethical consideration | The study adhered to CONSORT guidelines [ | PMC10166496 | ||
Certification of analysis | To ensure a high quality standardized formulations, the raw material was authenticated and the product was laboratory tested and certified by Prof JU Iyasele of Chemistry Department, University of Benin, Nigeria in accordance with Institute of Public analyst of Nigeria Decree no 100 of 1992. | PMC10166496 | ||
Results | PMC10166496 | |||
Baseline characteristics | Between February 27, 2020, and February 20, 2022, two hundred and sixty seven participants were assessed for eligibility, 72 participants were excluded for different reasons (58 did not meet the inclusion criteria: HIV/AIDS (25); first trimester pregnancy (17) and declined to participate (16)), while 95 eligible partic... | PMC10166496 | ||
Flowchart of the participants. | Of the 95 participants, 85 were pregnant: Mojeaga group (n = 42) and standard-of-care group (n = 43), while 10 were puerperal women (Mojeaga group (n = 6) and standard-of-care group (n = 4). So far, all 95 participants completed the treatment and were included in analysis.As shown in | PMC10166496 | ||
Distribution of sociodemographic variables across research groups. | Abbreviations: BMI = Body mass index; SSCE = Senior school certificate examination; OND = Ordinary National diploma; HND = Higher national diploma; BSC = Bachelor of science; SD = Standard deviationAdditionally, the baseline pre-therapy hematocrit level, pre-therapy serum electrolyte, urea and creatinine level and live... | PMC10166496 | ||
Comparison of pre-treatment serum variables between research groups. | Abbreviations: Na (NR) = Sodium (Normal range: 135–145); K = Potassium (NR 3.5–5.5); Cl = Chloride (NR 96–106); Bicarbonate (NR 21–31); Urea (NR 1.7–9.1); Creatinine (NR 53–106); AST = Aspartase transaminase (NR 1–40); ALP = Alkaline phosphatase (NR 60–170); ALT = Alanine transaminase (NR 1–40); Hematocrit (NR 30–54); ... | PMC10166496 | ||
Primary endpoints | PMC10166496 | |||
Median rise in hematocrit values | The median rise in hematocrit values at two weeks follow-up was significantly higher in Mojeaga group (10.00±7.00% vs 6.00±4.00%; p<0.001). Similarly, the median hematocrit values at two weeks follow-up were significantly higher in Mojeaga group (31.00±2.00% vs 27.700±3.00%; p<0.001). This is shown in | PMC10166496 | ||
Comparison of hematocrit parameters (primary outcome) among research groups after treatment. | Abbreviations: IR = interquartile range | PMC10166496 | ||
Comparison of symptom resolution between research groups pre and post-therapy. | PMC10166496 | |||
Proportion of participants with persisting anemic symptoms (epigastric pain, weakness, dizziness) at two weeks after initial therapy | Persistent anemic symptoms were reported in 4.2% of the Mojeaga group and 8.5% of the control group (p = 0.329). There were no cases of treatment failure. | PMC10166496 | ||
Comparison of incidence of fetal adverse events among research groups. | PROM, Premature rupture | Abbreviations: PROM = Premature rupture of fetal membranes;Not available* = Those that was recruited at puerperal period. | PMC10166496 | |
Frequency of adverse effects in research groups during treatment. | PMC10166496 | |||
Comparison of serum electrolyte and function tests of all research participants at post-therapy. | Abbreviations: Na (NR) = Sodium (Normal range: 135–145); K = Potassium (NR 3.5–5.5); Cl = Chloride (NR 96–106); Bicarbonate (NR 21–31); Urea (NR 1.7–9.1); Creatinine (NR 53–106); AST = Aspartase transaminase (NR 1–40); ALP = Alkaline phosphatase (NR 60–170); ALT = Alanine transaminase (NR 1–40); Hematocrit (NR 30–54); ... | PMC10166496 | ||
Median levels of liver function parameters (AST, ALT and ALP) at two weeks after initial therapy | As shown in | PMC10166496 | ||
Discussion | toxicity, congenital anomalies, hepatic and renal functions, anemia | ANEMIA IN PREGNANCY, STILL, ADVERSE EVENTS, RECRUITMENT, ANEMIA, WORMS, PRETERM LABOR, DISEASES | This trial which is the first positive randomized trial involving Mojeaga therapy in women with anemia shows that Mojeaga therapy improves anemia compared with the use of standard of care alone. Until now, treatment recommendations for moderate and severe anemia in pregnancy and gynecological patients were based on the... | PMC10166496 |
Conclusion | congenital anomalies, anemia | ADVERSE EVENTS, ANEMIA DURING PREGNANCY, ANEMIA | In conclusion, based on the findings of our study, Mojeaga should be considered a new adjuvants to standard-of-care option for pregnant and puerperal women with anemia. Mojeaga remedy is safe for treating anemia during pregnancy and puerperium without increasing the incidence of congenital anomalies, low birthweight, p... | PMC10166496 |
Supporting information | PMC10166496 | |||
CONSORT 2010 checklist of information to include when reporting a randomised trial*. | (DOC)Click here for additional data file.(DOCX)Click here for additional data file.(XLSX)Click here for additional data file.The study was coordinated by the Effective Care Research Unit at Nnamdi Azikiwe University University, Awka, Nigeria. The authors appreciate the help of the staff of Nnamdi Azikiwe University Uni... | PMC10166496 | ||
Background and purpose | cardioembolic stroke, cardioembolic ischemic stroke | The efficacy and safety of tirofiban in endovascular therapy for cardioembolic ischemic stroke patients remain controversial. This study aimed to evaluate the role of intravenous tirofiban before endovascular therapy in cardioembolic stroke. | PMC10621173 | |
Methods | sICH, stroke, cardioembolism, Vessel Occlusion Stroke, disability | INTRACRANIAL HEMORRHAGE, STROKE | This post hoc analysis utilized data from the RESCUE BT (Endovascular Treatment With versus Without Tirofiban for Patients with Large Vessel Occlusion Stroke) trial, which was an investigator-initiated, randomized, double-blind, placebo-controlled trial. Participants were randomized to receive either tirofiban or a pla... | PMC10621173 |
Results | cardioembolic stroke | A total of 406 cardioembolic stroke patients were included in this study, with 212 assigned to the tirofiban group and 194 assigned to the placebo group. Tirofiban treatment did not correlate with a favorable shift towards a lower 90-day mRS score (adjusted common odds ratio [OR], 0.91; 95% CI 0.64–1.3; | PMC10621173 | |
Conclusions | sICH, disability, cardioembolic stroke | Tirofiban treatment was not associated with a lower level of disability and increased the incidence of sICH after endovascular therapy in cardioembolic stroke patients. | PMC10621173 | |
Keywords | PMC10621173 | |||
Introduction | Ischemic stroke, cardioembolic stroke | SECONDARY, ISCHEMIC STROKE | Ischemic stroke remains a significant global health burden, contributing to substantial morbidity and mortality rates [Tirofiban, a glycoprotein IIb/IIIa receptor inhibitor, has gained attention as a potential adjunctive therapy in the context of EVT for cardioembolic stroke [In this secondary analysis of the RESCUE BT... | PMC10621173 |
Methods | PMC10621173 | |||
Study design and participants | stroke, vessel occlusion, acute ischemic stroke, cardio-embolism | STROKE | The RESCUE BT trial was a prospective, investigator-initiated, double-blind, randomized, placebo-controlled trial aimed at assessing the safety and efficacy of intravenous tirofiban versus placebo prior to EVT in acute ischemic stroke with large vessel occlusion from 55 hospitals in China between October 2018 and Octob... | PMC10621173 |
Etiological identification of Cardiac embolism | cardioembolic stroke | ACUTE STROKE | In this study, we implemented a meticulous and comprehensive approach for the etiological identification of cardioembolic stroke. Data were collected from various sources, including case report forms and source documents, encompassing comprehensive medical history, clinical features, laboratory tests, 24-h electrocardi... | PMC10621173 |
Treatments | stroke, angioplasty | STROKE, DEEP VEIN THROMBOSIS | Eligible subjects were randomly assigned to the tirofiban group or the control group. The tirofiban group received intravenous bolus and continuous infusion of tirofiban, while the control group received saline placebo. Tirofiban was administered as a 10 μg/kg bolus, followed by a maintenance infusion of 0.15 μg/kg/min... | PMC10621173 |
Variables and imaging assessment | ischemic injury, Thrombolysis, Stroke, Cerebral Ischemia | CEREBRAL ISCHEMIA, STROKE | During the enrollment process, demographic variables, vascular risk factors, baseline NIHSS score, treatment information, and workflow measures were recorded. To ensure consistency and reliability in the evaluation process, all imaging data were reviewed by the imaging core laboratory of the RESCUE BT. The determinatio... | PMC10621173 |
Outcomes | The primary outcome of this study was to assess the proportion of patients achieving functional independence after 90 days, defined as a modified Rankin Scale (mRS) score of 0–2 [ | PMC10621173 | ||
Statistical analysis | Patient characteristics and clinical outcomes in the two groups were reported using descriptive statistics, including number (percentage) or median and interquartile range. Categorical variables were analyzed using the χ [ | PMC10621173 | ||
Results | PMC10621173 | |||
Discussion | bleeding, sICH, cardioembolic, cardioembolic stroke, platelet aggregation | BLEEDING | This paper reports on a post hoc analysis of the RESCUE BT randomized trial, which aimed to investigate the efficacy of tirofiban for patients presenting with cardioembolic LVO within 24 h of onset. The results demonstrated that the administration of intravenous tirofiban prior to EVT didn’t improve the rate of functio... | PMC10621173 |
Conclusion | bleeding, sICH, cardio-embolism, cardioembolic stroke | SECONDARY, BLEEDING | The secondary analysis conducted in the RESCUE BT trial, with a specific focus on the cardio-embolism subgroup, has provided concerning insights into the concomitant administration of tirofiban and EVT. Our analysis has revealed a significant association between tirofiban usage and an increased risk of sICH among patie... | PMC10621173 |
Acknowledgements | We are grateful to all patients and investigators in the RESCUE BT trial. | PMC10621173 | ||
Author contributions | BR and ZY: the conception and design of the study. WZ, ZQ, XY and FL: acquisition of data. LG, YY, RM and ZL: analysis and interpretation of data. YL, JZ and HZ drafting the article or revising it critically for important intellectual content. ZY, TL, JF and GT: final approval of the version to be submitted. | PMC10621173 | ||
Funding | This study was supported by the Sichuan Provincial Central Leading Local Science and Technology Development Special Project. No.2021ZYD0106. | PMC10621173 | ||
Availability of data and materials | All data relevant to the study are included in the article or supplement. Further inquiries on data availability can be directed to the corresponding authors. | PMC10621173 | ||
Declarations | PMC10621173 | |||
Ethics approval and consent to participate | The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The study protocol received approval from the ethics committee of Xinqiao Hospital, Army Medical University, as well as the relevant ethics committees at all participating centers. | PMC10621173 | ||
Competing interests | All authors declare that they have no competing interests in the study. | PMC10621173 | ||
References | PMC10621173 | |||
Background | MH, opioid use disorder | Considering different factors, such as high withdrawal rates in methadone maintenance treatment (MMT) programs alongside mental health (MH) problems appearing in patients with opioid use disorder and the lack of prior research on the effect of zinc supplementation in this respect, the present study aimed to investigate... | PMC9817328 | |
Methods | opioid use disorder, Depression, Anxiety | RELAPSE | For this purpose, a randomized controlled trial with a clinical basis was fulfilled on a total of 68 patients with opioid use disorder receiving MMT, allocated to two groups, viz. intervention, and control (each one consisting of 34 individuals). Then, the participants in the intervention group were given zinc suppleme... | PMC9817328 |
Findings | Compared to the control group, the likelihood of drug use ( | PMC9817328 | ||
Conclusion | MH, opioid use disorder | Accordingly, it was concluded that zinc supplementation could reduce the PoR and improve MH problems in patients with opioid use disorder experiencing MMT. However, further research is recommended to fill the gaps. | PMC9817328 | |
Trial registration | The research protocol has also been listed on the Iranian Registry of Clinical Trials (IRCT) with code no. IRCT2020050904736N1. | PMC9817328 | ||
Keywords | PMC9817328 | |||
Background | anxiety, MH, Behavioral impairments, aggression, opioid use disorder, depression, irritability, affective dysregulation | DISORDER, ZINC DEFICIENCY, DYSFUNCTION, DISORDERS | As one of the first-line treatments for opioid use disorder, methadone maintenance treatment (MMT) seems to be a long-acting or permanent therapy that replaces opioids with other safe alternatives to control physical and mental problems facing patients with opioid use disorder [The evidence further suggests that many p... | PMC9817328 |
Aim | MH, opioid use disorder | Considering the high withdrawal rate in methadone maintenance treatment (MMT) programs alongside mental health (MH) problems appearing in patients with opioid use disorder and the lack of prior research on the effect of zinc supplementation on PoR and MH status in patients with opioid use disorder undergoing MMT, the p... | PMC9817328 | |
Methodology | PMC9817328 | |||
Research design | opioid use disorder | This study was a randomized, single-blind, parallel, two-arm clinical trial on patients with opioid use disorder receiving MMT in an addiction treatment clinic in an urban area of Iran from April 2021, lasting three months. The research protocol was also listed on the Iranian Registry of Clinical Trials (IRCT) with c... | PMC9817328 | |
Participants | schizophrenia, opioid use disorder, bipolar disorder, psychosis | The statistical population included adult patients with opioid use disorder undergoing MMT. The inclusion criteria in this study were the willingness to participate, age over 18, literacy, drug use confirmed by positive urine tests, taking methadone as supervised by a physician for at least three months, and no chronic... | PMC9817328 | |
Data collection | Depression, Anxiety | RELAPSE | The study data were collected using the Demographic Survey Form (DSF), the Relapse Prediction Scale (RPS), and the Depression, Anxiety, and Stress Scale 21 (DASS-21) before, one month after, and three months after the intervention (i.e., the completion of the intervention program). | PMC9817328 |
DSF | The DSF consisted of items focused on the participants’ age, gender, marital status, living conditions (single or with family), smoking status (cigarettes or hookahs), education level, and occupation. | PMC9817328 | ||
RPS | The 45-item RPS was administered to assess the PoR. Each item included a situation in which the respondent could rate the likelihood of drug use and drug craving [ | PMC9817328 | ||
DASS-21 | MH | The DASS-21 was implemented to measure the MH status of the study participants. Lovibond and Lovibond [ | PMC9817328 | |
Intervention program | The participants allocated to the intervention group were visited by a physician every two weeks, and then received a two-week supplement of zinc combined with methadone as planned. The daily dosage of the zinc supplement was about 12 mg. The supplement used in this study was Suzin Zinc Sulfate, made by Alhawi Pharmace... | PMC9817328 | ||
Data analysis | MH | The SPSS Statistics software package (ver. 23) was used for the data analysis. To this end, the data from the intervention and control groups were summarized descriptively, using frequency and percentage for the categorical variables and mean and standard deviation (SD) for the continuous ones. The Kolmogorov–Smirnov t... | PMC9817328 | |
Discussion | gastrointestinal tract function, anxiety, abdominal pain, MH, vomiting, constipation, opioid use disorder, malnutrition, depression, anorexia | INFLAMMATION, MALNUTRITION, ZINC DEFICIENCY, OXIDATIVE STRESS, GASTROESOPHAGEAL REFLUX DISEASE, ANOREXIA, COMPLICATIONS | This study aimed to investigate the effect of zinc supplementation on the PoR and MH in patients with opioid use disorder undergoing MMT, wherein the results indicated that zinc supplementation could reduce the PoR and improve the MH status in such individuals. As no studies had so far assessed the effect of zinc suppl... | PMC9817328 |
Limitations | MH, opioid use disorder | BLIND | To interpret the findings, there are some limitations in the present study that should be considered. First, this clinical trial was conducted in only one addiction treatment clinic located in an urban area of Iran, which could reduce the generalizations to all patients with opioid use disorder undergoing MMT. Second... | PMC9817328 |
Implications for clinical practice | MH, opioid use disorder | This study has some implications for clinical practice. In view of that, the findings highlight the effect of zinc supplementation on reducing the PoR and improving MH in patients with opioid use disorder experiencing MMT. Therefore, healthcare providers can introduce zinc supplements into the treatment plans for such ... | PMC9817328 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.